Friday, September 23, 2016

Monkeypox and Smallpox Continued


Some researchers question whether smallpox was ever truly exterminated. After WHO launched its global vaccination campaign against variola in 1967, suspected cases of smallpox were labeled as monkeypox.

Lancet published a report in 1972 that stated that WHO's program to eradicate smallpox “can only be successful in the absence of a non-human reservoir for smallpox virus.”

However, the author of the report identified several poxviruses affecting both humans and animals, and conceded that the monkeypox virus can cause clinical smallpox in humans.

In 1976, monkeypox antibodies in humans were discovered in Nigeria and the Ivory Coast. The monkeypox virus was indistinguishable by laboratory methods from the smallpox virus.

Orthopoxviruses, the genera to which vaccinia, variola, cowpox, and monkeypox belong, have a high degree of similarity, with a “propensity for genetic recombination.” Monkeypox and smallpox produce exact clinical symptoms, with one insignificant difference: monkeypox also causes swelling of the cervical and inguinal (groin) lymph nodes.

In 1979, new research indicated that several animal species, including some rodents, may be carriers of variola-like viruses virtually identical to cowpox and monkeypox viruses. In fact, several poxviruses from animal sources were tested and shown to behave like variola/smallpox viruses.

Scientists are “wondering whether the specter of smallpox might be rising form the dead, perhaps reincarnated in its close relative monkeypox, which is alive, well, and spreading in Central Africa.” According to Dr. Peter Jahrling of the U.S. Army Medical Research Institute of Infectious Diseases, for all practical purposes, smallpox is back. [Radio National. “The Health Report: Monkeypox.” Australian Broadcasting Corporation (September 1, 1997)]
           
Bioterrorism, Dark Winter and the New Smallpox Vaccine

During the 1970s experimentation with smallpox virus was conducted, and two medical researchers were even killed in England as a result. To reduce the risk of future accidents, all remaining known samples were moved to a CDC facility in Georgia and the State Research Center of Virology and Biotechnology in Novosibirsk, Siberia.

Numerous deadlines came and went to destroy the virus, with some scientists defending the need to preserve them...“for science!”

On November 15th, 2001, in the wake of 9/11, the Bush administration postponed indefinitely any decision to eliminate seed stocks of the microbe.

Even though smallpox hadn't occurred in the U.S. since 1949, the government had stockpiled 15 million doses of the vaccine. However, the disgusting concoction was severely archaic:
The Centers for Disease Control and Prevention, in Atlanta, has a reserve of roughly 15 million doses of smallpox vaccine. That vaccine, which is not available to the public, was manufactured using a method that dates from the 1700s.

The method involves infecting calves with a related virus, vaccinia; the resulting pus is used in the making of the vaccine. That process is considered barely acceptable for human vaccine today.

Not only that, but the vaccine was known to cause inflammation of the brain as well as numerous other side effects, including smallpox itself and death. Sources:
Greenberg, M. “Complications of vaccination against smallpox.” Am J Dis Child 1948;76:492-502

Cangemi, VF. “Acute pericarditis after smallpox vaccination.” *N Engl J Med 1958;258:1257-9.

Copeman, PWM., et al. “Eczema vaccinatum.” British Medical Journal 1964;2:906-8.


Fulginiti VA., et al. “Progressive vaccinia in immunologically deficient individuals.” Birth Defects Original Article Series. 1968;4:129–145.

Marmelzat, WL. “Malignant tumors in smallpox vaccination scars.” Arch Dermatol 1968;97:406.


Holtzman, CM. “Postvaccination arthritis.” NEJM 1969;280:111-2.


In 1997, four years before the 2001 terrorist attacks, the Department of Defense contracted with DynPort Vaccine Company to produce a new smallpox vaccine. In September of 2000, one year before the terrorist attacks, the CDC contracted with OraVax (which changed its name to Acambis) to produce a new smallpox vaccine.

Some researchers were puzzled by these actions since smallpox was supposedly eradicated and authorities were debating whether to destroy all of the remaining seed stocks of the virus. According to Dr. Margaret Hamburg, of the Department of Health and Human Services, “A lot of people thought this was a crazy idea, to make a new vaccine when the disease didn't exist.”

In June 2001, before the 9/11 attacks, a team of bioterrorism specialists led by the Johns Hopkins University Center for Civilian Biodefense Studies conducted a smallpox epidemic exercise ominously called Dark Winter.

Within two months after the hypothetical epidemic started, three million people were infected. Dark Winter ended with the collapse of interstate commerce, crowds rioting in the streets, and the nation moving towards martial law.

However, like any theoretical exercise, conclusions are predicated on the underlying assumptions. One key assumption was that each person with smallpox would infect at least 10 other people and that those 10 people would each infect at least 10 more people and so on.

But a recent study published in Emerging Infectious Diseases regards those infection rates as grossly unrealistic. The authors of the study looked at data from numerous smallpox outbreaks and reported that on average less than one person was infected per infectious person.

In all outbreaks, some infected persons did not transmit a single case of smallpox to another person. The CDC researchers concluded “the probability that the average transmission rate will be greater than two cannot be demonstrated reliably.”

Even though the Dark Winter simulation was severely flawed, Dr. Henderson, the “team leader” who also led WHO's global effort to eradicate smallpox, concluded that the threat was real and recommended 100 to 135 million doses.

Less than 10 days after 9/11, Dick Cheney was shown a video of the Dark Winter simulation and urged to increase the production of smallpox vaccine.

On October 24, 2001, President Bush asked Congress for $509 million to develop and produce a new smallpox vaccine. He solicited bids for the job from several pharmaceutical companies, insisting on 300 million doses—one dose for every American—within the shortest possible time, not to exceed one year.

The new vaccine was expected to be made from a “diploid cell substrate” (human embryo) or from animal tissue cell cultures, including those with “tumorigenic potential.”

Ideally, it would not cause adverse reactions, would not be dangerous to people with immune system deficiencies, and would have the capacity to defeat genetically altered strains of variola. But researchers provided no evidence that the new vaccine would cause fewer adverse reactions than the old vaccine.

Furthermore, experts were very concerned about “the transmissibility of vaccinia virus from a recently vaccinated person to a susceptible host.” In other words, some people—no one knows how many—will develop smallpox by coming into contact with a recently vaccinated person.
Franklin Top, a biotechnology expert and previous commander of the Walter Reed Army Institute of Research, declared that “reactogenicity” is going to be a problem.

Dr. Mark Buller, a virologist specializing in safer smallpox treatments at St. Louis University, boldly pronounced: “I would not even consider having my family vaccinated. I'm more likely to be hit riding my bike to work than be hit by a smallpox episode in my own life. [Stolberg, SG. “Immunization: vast uncertainty on smallpox vaccine.” New York Times (October 19, 2001)]

Potential vaccine recipients must also understand that scientists may never be able to create a vaccine that can protect against mutated strains of the virus. Dozens of strains already exist. New permutations of the variola microbe could be developed by bioterrorists rendering a new vaccine worthless, thus subjecting recipients of the shot to the inherent risk of serious adverse reactions without the expected benefit.

In 2002, the U.S. government tested their existing smallpox vaccine on 200 “fit and healthy” college students. Following vaccination, 75 had high fevers, one-third missed at least one day of work or school, and several were put on antibiotics because their blisters resembled a bacterial infection.

Dr. Kathy Edwards, the physician overseeing the study, commented on the side effects: “I can read all day about it, but seeing it is quite impressive. The reactions we saw were really quite remarkable.”
           
In late 2002, smallpox vaccination was reinstated for U.S. military personnel. In early 2003, the program was expanded to include civilians considered at high risk during a smallpox outbreak (mostly healthcare and emergency service workers).

Shortly thereafter, several vaccinated people experienced serious adverse reactions, including heart problems. For example, a Maryland woman died from a hearth attack after being injected with the shot.

These reports compelled the CDC to release a fact sheet on the smallpox vaccine to address the many concerns, admitting, “There is evidence suggesting that smallpox vaccination may cause cases of heart inflammation (myocarditis), inflammation of the membrane covering the heart (pericarditis), and a combination of these two problems....Heart pain (angina) and heart attack have also been reported after smallpox vaccination.”

In 2005, the Journal of the American Medical Association published a study that assessed the safety of the government's program. The study documented nearly a thousand adverse events, including 85 hospitalizations (numerous cases of myocarditis or pericarditis), and three deaths. The report ends by suggesting:
Additional reduction of overall vaccinia adverse events might be achievable through study of cardiac and dermatological risk factors, a better understanding of vaccinia host-pathogen interaction, and development of a less reactogenic vaccinia vaccine.

In 2007, a two-year-old and his mother were infected with “eczema vaccinatum” after the father, a U.S. army soldier, was recently vaccinated against smallpox.

Also in 2007, an experimental smallpox vaccine called ACAM2000 (made by Acambis) was declared safe and effective by the FDA, despite the fact that clinical trials of this vaccine were halted three years earlier when several people developed myopericarditis after receiving the new vaccine.

According to the FDA, ACAM2000 is “nearly as effective” as the older smallpox vaccine, Dryvax, and poses “similar risks of serious side effects.”

As for Dryvax, the listed adverse reactions include autoinoculation (transfer of the virus to other parts of the body) affecting the face, nose, mouth, genitalia and rectum; infection of the eye resulting in blindness; post-vaccinal encephalitis, encephalomyelitis, encephalopathy, progressive vaccinia, eczema vaccinatum, Stevens-Johnson syndrome, neurological sequelae, and death.

However, even while U.S. Homeland Security was contemplating mandating the smallpox vaccine, not every government official was convinced. For example, Tommy Thompson of Health and Human Services said his department had no plans for a mandatory vaccination program, citing horrendous side effects as the principal reason. [Neergaard, L. “Health officials review smallpox plan.” Associated Press (October 19, 2001)]

Dr. Anthony Fauci, director of the National Institute of Allergy and Infectious Diseases, also opposed the idea, declaring that side effects were too numerous and too severe. [Stolberg, SG.]

Many pediatricians can't distinguish between smallpox and chickenpox, according to the results of a survey published in 2006 by Clinical Pediatrics.

Fifty-nine percent of the responders were unable to differentiate chickenpox from smallpox, and the majority would not accept vaccination in the absence of an outbreak and would not recommend smallpox vaccine to their patients. Even in previously vaccinated pediatricians, willingness to receive smallpox vaccine is poor...

Despite the well-documented concerns about the safety of the smallpox vaccine and the threat (and loss of civil liberties) associated with mandatory vaccines, on October 23, 2001, the CDC unveiled new legislation, The Model State Emergency Health Powers Act, “giving public health officials and state governors the authority to arrest, vaccinate, medicate, and quarantine anyone they deem either unprotected from, or a threat to spread, infectious disease (see Section 504a—Vaccination and treatment).”

Local police and the U.S. military, by way of the National Guard, would enforce the law. Previous laws permitting medical, religious, or philosophical exemptions would be repealed.

In response to this legislation, Dawn Richardson of PROVE, a vaccine awareness organization, declared:
Everyone who values our freedoms and rights in this country needs to commit to educating family and friends about the dangers of such an unchecked medical dictatorship.

Because there has been no research into the biological mechanisms that predispose people to vaccine reactions and there has been no effort to screen out these individuals, this type of action should be condemned; it will create unfathomable human suffering and sacrifice. [Richardson, D. “Danger: forced vaccination for all under CDC's proposal.” PROVE newsletter (November 2, 2001)]

This legislation also exempts the State, the police, and public health authorities from any liability. “If an individual opposes vaccines, is force-inoculated and dies, the perpetrators cannot be prosecuted.”

The ACLU also weighed in quite heavily against the MSEHPA.

Because of the increasing number of reported side effects, Congressman Henry Waxman was forced to state the obvious: “The president has asked healthcare workers to volunteer to be immunized so that they can serve society. In turn, society should help them if they are hurt when they volunteer.”

In response to these concerns, in 2006 the U.S. government published the “final rules” to the Smallpox Vaccine Injury Compensation Program. The goal was to provide “benefits to public health and medical response team members and others who are injured as a result of receiving the smallpox vaccine.”

Also, “unvaccinated individuals injured after coming into contact with a vaccinated member of an emergency response plan, or with a person with whom the vaccinated person had contact, or their survivors may be eligible for the same program benefits.”

In conclusion, Neil Miller offers a crude, but damning, summary of this alternative perspective of the history of smallpox and the smallpox vaccine:

1  Being with unsanitary living conditions and poor nutritional awareness. This results in regional and self-limiting outbreaks of smallpox. 

2  Conduct human experiments with variolation—the practice of inserting viral matter from a smallpox victim into a deliberate cut on a healthy person.

3  When this fails, conduct human experiments with cowpox, horsepox, and horsegrease cowpox. 

4  When this fails, deny it.

5  When this fails, blame it on “spurious” cowpox, improperly administered injections, or too few puncture marks...and recommend re-vaccination. 

6  When this fails, manipulate statistics by altering medical records and falsifying death certificates...and mandates the smallpox vaccine.

When people refuse the shot, vaccination rates drop, and cases of smallpox dwindle...take full credit for eradicating the disease.

No comments:

Post a Comment